

controlled in June and July, 1973, paying special attention to indications of diversion and to chemical research on the abusability and dependence forming characteristics of these substances. It was further decided that eighteen months under control should provide sufficient information upon which our review could then be based.

DEA, after discussions with the National Institute on Drug Abuse and the Food and Drug Administration, began its review as scheduled.

In addition to employing our own resources on the monitoring program, DEA contracted in March 1975 with the Stanford Research Institute to assist in the development of a method to schedule drugs objectively. That study concentrated on the anorectics as models. We received the results of the Stanford study in April of this year. We have also received, under contract with the Research Planning Corporation, the results of a study devoted in major part to identifying and quantitating abuse levels of the drugs in question.

On May 13, 1975, DEA forwarded a letter to each major manufacturer of a non-amphetamine anorectic